


Click to verify































[illegible]



[phenylhydrazine](#) in THF either the position of alkylation is assumed to follow previous examples. *Gazzetta Chimica Italiana*. 1905;35:p. 373. [Google Scholar][43.Naik A. D., Marchand-Braunert J., Garcia Y. A simplified approach to N-and N-linked 1, 2, 4-triazoles by transamination. Synthesis. 2008;2008\(1\):149154. doi: 10.1055/s-0007-983986.](#)

[Google Scholar][44.Wiley R. H., Hart A. J. Reaction of diformylhydrazine with aminoheterocycles. The Journal of Organic Chemistry. 1953;18\(10\):13681371. doi: 10.1021/jo00160a016.](#)

[Google Scholar][45.Liu B., Zhang X.-C., Wang Y.-F. The syntheses, structures and fluorescent properties of two 3-D hydrogen-bonded frameworks constructed from 1,2,4-triazole derivatives and metal ions. \*Synthetic Metals\*. 2009;159\(1\):109116. doi: 10.1016/j.synthe.2008.09.001.](#)

[Google Scholar][46.Kumar S., Kishor P., Kumar V., Singh S. Synthesis and characterization of novel 1,2,4-triazole salts. \*Journal für Praktische Chemie\*. 1988;330\(3\):325337. doi: 10.1002/prac.1988330032.](#)

[DOI] [PubMed] [Google Scholar][47.Pellizzari G. Nuova sintesi del triazolo e dei suoi derivati. Gazzetta Chimica Italiana. 1894;24:222229.](#)

[Google Scholar][48.Potts T. The chemistry of 1, 2, 4-triazoles. Chemical Reviews. 1961;61\(2\):87177. doi: 10.1021/cr60210ao01.](#)

[DOI] [Google Scholar][49.von Meyer W. C., Greenfield S. A., Seidel M. C. Wheat leaf rust: control by 4-butyl-1, 2, 4-triazole, a systemic fungicide. Science. 1970;169\(3949\):997998. doi: 10.1126/science.169.3949.997.](#)

[PubMed] [Google Scholar][50.Tombo G. M. R., Bellu D. Chirality and crop protection. Angewandte Chemie International Edition in English. 1991;30\(10\):11931215. doi: 10.1002/ange.199111933.](#)

[DOI] [Google Scholar][51.De Beule K., Van Gestel F. Pharmacology of itraconazole. Drugs. 2001;61\(Supplement 1\):2737. doi: 10.2165/000030495-2001610001-0003.](#)

[PubMed] [Google Scholar][52.Weisterberg D. P., Voyack M. J. Onychomycosis: current trends in diagnosis and treatment. American Family Physician. 2013;88\(11\):162770. \[PubMed\] \[Google Scholar\]\[53.Gupta A., Richardson M., Paquet M. Systematic review of oral treatments for seborrheic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2014;28\\(12\\):1626. doi: 10.1111/ijd.12197.\]\(#\)](#)

[DOI] [PubMed] [Google Scholar][54.Rossi S. Australian Medicines Handbook. Adelaide: 2006. \[Google Scholar\]\[55.Dayer M. R. Old drugs for newly emerging viral disease, COVID-19: Bioinformatic Prospective. 2020. M. A., Zhu E. S., Thompson G. R. In 3rd isavuconazole in the treatment of invasive aspergillus and mucormycosis infections. Infection and Drug Resistance. 2016;9:799. doi: 10.2147/IDR.S81416.\]\(#\)](#)

[DOI] [PMC free article] [PubMed] [Google Scholar][56.Michel M., Kaufmann C. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clinical Infectious Diseases. 2015;61\(10\):15581565. doi: 10.1093/cid/civ571.](#)

[DOI] [PubMed] [Google Scholar][57.Patel T., Dhillon S. Efinaconazole: first global approval. \*Drugs\*. 2015;75\(1\):161172. doi: 10.1007/s12675-014-0616-2.](#)

[DOI] [PubMed] [Google Scholar][58.Tatsumi Y., Nagashima M., Shibahashi T., et al. Mechanism of action of efinaconazole, a novel triazole antifungal agent. Antimicrobial Agents and Chemotherapy. 2013;57\(5\):24052409. doi: 10.1128/AAC.020632-12.](#)

[DOI] [PMC free article] [PubMed] [Google Scholar][59.Schiller D. S., Fung H. B. Posaconazole: an extended-spectrum triazole antifungal agent. Clinical Therapeutics. 2007;29\(9\):18621886. doi: 10.1016/j.clinthera.2007.09.015.](#)

[DOI] [PubMed] [Google Scholar][60.Rachwalski E. J., Wierczkiewicz J. L., Scheetz M. H. Posaconazole: an oral triazole with an extended spectrum of activity. Annals of Pharmacotherapy. 2008;42\(10\):14291438. doi: 10.1345/apah.1L005.](#)

[DOI] [PubMed] [Google Scholar][61.Li B., Brown N., Chau A. S., et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. Journal of Antimicrobial Chemotherapy. 2003;53\(1\):7480. doi: 10.1093/acd/k027.](#)

[DOI] [PubMed] [Google Scholar][62.Walsh T. J., Raad I., Patterson T. F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clinical Infectious Diseases. 2007;44\(1\):212. doi: 10.1086/508774.](#)

[DOI] [PubMed] [Google Scholar][63.Raad I. I., Hachem R. Y., Herbrecht R., et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancies and other conditions. Clinical Infectious Diseases. 2006;42\(10\):13981403. doi: 10.1086/503425.](#)

[DOI] [PubMed] [Google Scholar][64.Colonel B. A., Hancock C. A., Guy R. K., Kyle D. E. Phenotypic screens reveal posaconazole as a rapidly acting amebicidal combination partner for treatment of primary amoebic meningoencephalitis. \*The Journal of Infectious Diseases\*. 2012;207\(7\):10951103. doi: 10.1093/infdis/jis622.](#)

[DOI] [PubMed] [Google Scholar][65.Colinvaux A., Demaree C., Spilner B., Linson B., Wittebole X., Wouters D., Sneyders D. Drug-drug interactions in the intensive care unit: do they really matter? Journal of Critical Care. 2012;27\(1\):1016.](#)

[DOI] [PubMed] [Google Scholar][66.Hong S. H., Kim H. J., Lee S. H., et al. Demographic characteristics of patients with invasive aspergillosis treated with voriconazole. \*Chest\*. 2006;130\(5\):14611466. \[DOI\] \[PubMed\] \[Google Scholar\]\[67.Omrani A. S., Almaghribi R. S. Complications of hematopoietic stem transplantation: fungal infections. Hematology/Oncology and Stem Cell Therapy. 2017;10\\(4\\):239244. doi: 10.1016/j.hemonc.2017.05.013.\]\(#\)](#)

[DOI] [PubMed] [Google Scholar][68.Herbrecht R., Denning D. W., Patterson T. F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine. 2002;347\(6\):408415. doi: 10.1056/NEJMoa020191.](#)

[DOI] [PubMed] [Google Scholar][69.Salvador Velez F. M., Sanchez Montalva A., Molina Romero I. Experimental and clinical treatment of Chagas disease: a review. The American Journal of Tropical Medicine and Hygiene. 2017;97\(5\):12891303. doi: 10.4269/ajtmh.16-0761.](#)

[DOI] [PubMed] [Google Scholar][70.Kumar S., Kimball A. B. New antifungal therapies for the treatment of onychomycosis. Expert Opinion on Investigational Drugs. 2009;18\(6\):727734. doi: 10.1517/13543780902810352.](#)

[DOI] [PubMed] [Google Scholar][71.Pasqualotto A. C., Thiele K. O., Goldani L. Z. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Current Opinion in Investigational Drugs. 2010;11\(2\):165174. \[PubMed\] \[Google Scholar\]\[72.Fallmer M., Messer S. A., Hollis R. J., Jones R. N. Antifungal activities of ravuconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi determined from SENTRY antimicrobial surveillance program. Antimicrobial Agents and Chemotherapy. 2002;46\\(4\\):10321037. doi: 10.1128/AAC.46.4.1032-1037.2002.\]\(#\)](#)

[DOI] [PMC free article] [PubMed] [Google Scholar][73.Martinez-Sanchez E. M., Rodriguez-Martin J. J., Arana J., et al. Antifungal activity of supratherapeutic concentrations of voriconazole against Aspergillus fumigatus strains isolated from immunocompromised patients. \*Antonie van Leeuwenhoek\*. 2010;98\(1\):101107. doi: 10.1007/s12220-010-9251-1.](#)

[DOI] [PubMed] [Google Scholar][74.Yamauchi H. Potential of ravuconazole and its prodrugs for the treatment of onychomycosis. Mycoses. 2016;59\(1\):101107. doi: 10.1111/myco.12362.](#)

[DOI] [PubMed] [Google Scholar][75.EBSE110. doi: 10.13314/mjm.16-00006.](#)

[DOI] [PubMed] [Google Scholar][76.Tran N. T., Zivin A., Mozaffarian D., Karmy-Jones R. Right atrial perforation secondary to implantable cardioverter defibrillator insertion. Canadian Respiratory Journal. 2001;8\(4\). doi: 10.1155/2001/257641.](#)

[DOI] [PubMed] [Google Scholar][77.Moberg W. K., Basarab G. S., Cuomo J., Liang P. H. Biologically Active Organosilicon Compounds: Functional Silylmethyltriaryloxides. ACS: 1987. \[DOI\] \[Google Scholar\]\[78.Bostanian N. J., Larocque N., Chouinard G., Coderre D. Baseline toxicity of several pesticides to Hyaliodios virens \\(Hymenoptera: Miridae\\) Pest Management Science: Formerly Pesticide Science. 2001;57\\(11\\):10071010. doi: 10.1002/pss.374.\]\(#\)](#)

[DOI] [PubMed] [Google Scholar][79.Eckert M. R., Rossall S., Selley A., Pitt B. D. L. Effects of fungicides on tuberoscye germination and mycelial growth of the phytopathogens Leprosapharia maculans and Diplodactylus \(phoma stem canker of oilseed rape\) Pest Management Science: Formerly Pesticide Science. 2010;66\(4\):396405. doi: 10.1002/pss.1890.](#)

[DOI] [PubMed] [Google Scholar][80.Ramani R., Shanker U. Removal of chlorpyrifos, thiamethoxam, and tebuconazole from water using green synthesized metal hexacyanoferrocene nanoparticles. Environmental Science and Pollution Research. 2018;25\(11\):1087810893. doi: 10.1007/s11356-018-1346-2.](#)

[DOI] [PubMed] [Google Scholar][81.Wang Z., Tian Z., Chen L., et al. Stereoselective metabolism and potential adverse effects of chiral fungicide triadimenol on Eremias argus. Environmental Science and Pollution Research. 2020;27\(8\):78237834. doi: 10.1007/s11356-019-07205-4.](#)

[DOI] [PubMed] [Google Scholar][82.Krmer W., Schirmeier M., Schirmacher M., et al. The demethylase CYP51A1 gene is overexpressed in Venturia inaequalis strains resistant to myclobutanil. Phytopathology. 2001;91\(1\):102110. doi: 10.1094/PHYTO.2001.91.1.10.](#)

[DOI] [PubMed] [Google Scholar][83.Allen J. W., Wolf D. C. Toxicity profiles in mice treated with hepatotumorigenic and non-hepatotumorigenic triazole conazole fungicides: propiconazole, triadimenol, and myclobutanil. Toxicological Pathology. 2006;34\(7\):853862. doi: 10.1080](#)

**Triazole antifungal side effects. Triazole antifungal examples. Triazole medication. What are triazole antifungals. Triazole fungicide.**